| Document |
Document Title |
|
WO/2012/013020 |
An anti-fatigue composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide. Experiments prove that the composition exhibits a significant anti-fatigue effect. In comparison with the effect attained by the single u...
|
|
WO/2012/013020 |
An anti-fatigue composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide. Experiments prove that the composition exhibits a significant anti-fatigue effect. In comparison with the effect attained by the single u...
|
|
WO/2012/011071 |
The present invention concerns a composition comprising a low dosage of at least one venom derived from a venomous snake, characterised in that said composition is diluted in an aqueous medium according to the Sequential Kinetic Activati...
|
|
WO/2012/008457 |
The present invention provides a composition for external application, which contains a vitamin A, a heparin analogue and an antioxidant. The present invention also provides a composition for external application for improving rough skin...
|
|
WO/2012/004875 |
[Problem] To provide an antioxidant which has an effective antioxidant effect without showing any side effects. [Solution] A novel substance represented by formula (1).
|
|
WO/2011/160252 |
Organic acid salts of Penehyclidine optical isomer, specifically compounds of formula (I), crystals, solvates or pro-drugs thereof are disclosed, in which n and HX are as defined in the specification. The methods for preparing compounds ...
|
|
WO/2011/162639 |
The invention relates to the field of synthesizing high molecular weight chemical compounds that exhibit biological activity for the production of highly effective pharmacological preparations and vaccines and, more specifically, to hete...
|
|
WO/2011/158089 |
Compositions comprising N-containing polymers to suppress the metal induced allergic reactions in sensitized subjects. More particularly, the inventive composition are intend to prevent allergies to immunogenic metals in a subject with a...
|
|
WO/2011/156729 |
The present invention is directed to methods of reducing mortality in a subject exposed to a lethal dose of radiation comprising administering to the subject an effective amount of a thrombin peptide derivative described herein. Also inc...
|
|
WO/2011/154630 |
The invention relates to a gaseous composition containing an effective amount of gaseous krypton for use via inhalation for preventing or treating a deficiency or failure of at least one peripheral organ in a patient. Preferably, it cont...
|
|
WO/2011/152751 |
The invention relates to the pharmaceutical industry, and specifically to a composition based on 6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone (ubinone, ubiquinone, coenzyme Q10) in liquid form, which can be used for the prophylax...
|
|
WO/2011/152330 |
Disclosed is an antioxidant which exhibits high antioxidation activity and can be used in food, drink or pharmaceutical products. An antioxidant that exhibits high antioxidation activity can be provided by obtaining a soybean protein hyd...
|
|
WO/2011/149011 |
Disclosed are: the compound represented by formula (1) or a salt thereof; and a manufacturing intermediate therefor. Said compound exhibits excellent antioxidant activity in a microsomal lipid peroxidation measurement system using rat-li...
|
|
WO/2011/143843 |
An atomizing formulation comprising plant extract and its preparation method are disclosed. The atomizing formulation consists of tea polyphenol, vitamin E, essence and diluent. Its preparation method comprises the steps of: crushing gre...
|
|
WO/2011/139897 |
α-tocopherol quinone is chemically reduced by combination with a reducing agent, such as tin (II) ion in the form of stannous chloride (SnCl2-2H20), or by chromium (III) ion, such as chromium (III) in the form of chromium chloride (CrCl...
|
|
WO/2011/139897 |
α-tocopherol quinone is chemically reduced by combination with a reducing agent, such as tin (II) ion in the form of stannous chloride (SnCl2-2H20), or by chromium (III) ion, such as chromium (III) in the form of chromium chloride (CrCl...
|
|
WO/2011/136573 |
The present invention relates to a yeast hydrolysate, which inhibits the deposition of fat around internal organs so as to treat or prevent obesity, and which has antioxidant activity. In addition, the present invention relates to a meth...
|
|
WO/2011/134019 |
The present invention relates to compounds and compositions useful in modulating the renin-angiotensin system (RAS) in cells, and in particular to compounds which, inter alia, act as angiotensin II antagonists by binding to angiotensin I...
|
|
WO/2011/136573 |
The present invention relates to a yeast hydrolysate, which inhibits the deposition of fat around internal organs so as to treat or prevent obesity, and which has antioxidant activity. In addition, the present invention relates to a meth...
|
|
WO/2011/124234 |
Synthesis of nano-hydroxyapatite by an organic-inorganic complexion route. Such material was injected intravenously into rats after the exposure of these rats to LD50 of toxic heavy metal. The prepared nano-hydroxyapatite success in repa...
|
|
WO/2011/123890 |
The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection). Preferred compounds of the invention are those of Formula (II), as follow...
|
|
WO/2011/117690 |
The present invention relates to the use of hydroxyl-2, 3- diarylxanthones (DAX) as therapeutic agent of pathologies due to reactive oxygen species. Certain polyhydroxy-2, 3-diaryl-9H-xanthen-9-ones present antioxidant properties much hi...
|
|
WO/2011/116216 |
Topical skin care compositions containing a combination of ascorbic acid or a derivative thereof, brown algae extract, and a blend of botanical extracts comprising cucumber extract, watercress extract, birch leaf extract, red clover extr...
|
|
WO/2011/113300 |
Compounds of formula (1) or a derivative thereof, acipimox, are used in combination with several chemotherapeutic agents for inhibition of toxicity or side effects caused by chemotherapeutic agents, while do not attenuate chemotherapeuti...
|
|
WO/2011/110661 |
An antioxidant composition is described for reducing oxidative stress in subjects undergoing hormonal contraceptive drug treatment. In particular, said composition has proved to be particularly suitable because, as well as being surprisi...
|
|
WO/2011/111577 |
Provided is an adsorption carbon which can effectively adsorb toxins, such as advanced glycation end-products (AGEs), within a living body. Also provided is an adsorbent which contains said adsorption carbon as the active ingredient. The...
|
|
WO/2011/107877 |
A compound, composition and method of making and using a compound of formula (1) are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, mesylates, hydrochloric salt, solvates and hydrates thereof. The com...
|
|
WO/2011/107870 |
A compound, composition, method of synthesizing and using the compound of formula (I) are disclosed. The compound of formula (I) also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharm...
|
|
WO/2011/107259 |
The subject invention relates to a chocolate or compound chocolate product comprising added functional ingredients including vitamin C, vitamin E, zinc, copper and, optionally, a xanthophyll. The invention further concerns the production...
|
|
WO/2011/107867 |
A compound, composition and method of making and using a compound of formula (1) are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, mesylates, hydrochloric salt, solvates and hydrates thereof. The com...
|
|
WO/2011/107881 |
A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceu...
|
|
WO/2011/105424 |
The purpose of the present invention is to find a ligand for a DCIR and to search for a stimulant and an antagonist for the DCIR. Specifically disclosed are: a dendritic cell immunoreceptor stimulant which contains keratan sulfate II (KS...
|
|
WO/2011/102310 |
Disclosed is a blood uric acid level lowering agent, which is derived from a natural material and can be ingested continuously for a long period. The blood uric acid level lowering agent comprises an enzymatic decomposition product of a ...
|
|
WO/2011/103536 |
The present disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications, such...
|
|
WO/2011/099031 |
This invention is based on strong antioxidants which are useful for all age group. The basic composition of ingredients are-EPA 150 mg, DHA 100 mg, Folic Acid 5 mg and Lycopene 50 mg. DHA is a major fatty acid in sperm and brain phosphol...
|
|
WO/2011/099526 |
Disclosed is a biocompatible solution which can deliver a sufficient quantity of hydrogen molecules into cells. Specifically disclosed is a hydrogen-containing hypotonic biocompatible solution which contains hydrogen molecules, contains ...
|
|
WO/2011/097372 |
Cocrystals of pterostilbene are disclosed, including: pterostilbene: caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene : glutaric acid cocrystal, and pterostilbene: piperazine cocrystal. The pterostilbene: caffeine...
|
|
WO/2011/097372 |
Cocrystals of pterostilbene are disclosed, including: pterostilbene: caffeine cocrystal, pterostilbene:carbamazepine cocrystal, pterostilbene : glutaric acid cocrystal, and pterostilbene: piperazine cocrystal. The pterostilbene: caffeine...
|
|
WO/2011/092290 |
There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
|
|
WO/2011/093469 |
Promotion of the expression of a redox-related factor in a living organism ensures safe and efficient reduction of oxidative stress in the organism, contributes to the maintenance of good health and prevents various diseases and symptoms...
|
|
WO/2011/089951 |
Disclosed are a prevention/treatment agent for diabetic retinopathy characterized by containing lutein; said prevention/treatment agent, an ameliorating agent for an electroretinogram, an apoptosis suppression agent for retinal ganglion ...
|
|
WO/2011/091357 |
The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subject...
|
|
WO/2011/080139 |
The present invention relates to amino alcohol derivatives of general formula (I). These derivatives possess an interesting activity in that they block the secondary products of lipid oxidative stress, and are consequently suitable for t...
|
|
WO/2011/078785 |
The present invention relates to novel compounds, and in particular to diacylglycerol (1, 3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional f...
|
|
WO/2011/079212 |
Provided herein are methods of culturing cells in vitro in order to exploit the biochemical production ability of the cells to make metabolites that are evaluated and harvested for their biological effects. Also provided are systems for ...
|
|
WO/2011/067653 |
The invention refers to a composition to treat or prevent in subjects with sub-clinical or acute mercury intoxication from dental amalgam, or a diagnostic tool thereof. The odontostamatologic composition comprising at least a non-resorba...
|
|
WO/2011/059021 |
Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, A represents a group that is represented by formula (A-1); R1a and R1b may be the same or different and each independentl...
|
|
WO/2011/059416 |
The invention relates to pharmacology, medicine, livestock breeding and poultry farming, and is directed towards producing agents and methods which can be used for prophylactic aims in order to reduce the risk of morbidity caused by nega...
|
|
WO/2011/059733 |
The present invention provides lipoic acid or derivatives thereof for use in graft stabilization of fat grafts. Mixing of lipoic acid or a derivative thereof with adipocytes or adipose tissue to be transplanted into a subject leads to mo...
|
|
WO/2011/058773 |
Disclosed is a composition which is capable of stably containing a carotenoid for a long period of time. The composition is characterized by containing (A) a carotenoid, (B) a middle chain saturated fatty acid triglyceride and (C) tocotr...
|
